Home
Partners
Academic/SME partners
-
Stichting Radboud Universitair Medisch Centrum (Radboudumc)
(The Netherlands) specializes in patient care, scientific research, teaching and training. Our mission is to have a significant impact on healthcare. We aim to be pioneers in shaping the healthcare of the future, in a person-centered and innovative way. In cooperation with partners, Radboud university medical center leads and coordinates Unite4TB. -
London School for Hygiene and Tropical Medicine (LSHTM)
(United Kingdom) is a global leader in public health, with cross-faculty interest in TB research and international high-impact clinical trials. LSHTM will participate in the overall academic leadership of the consortium as well as the implementation of the clinical trials through its network of TB clinical research sites in Asia. -
University of Oxford
(United Kingdom) The University of Oxford department of Tropical Medicine & Global Health is collaborating in UNITE4TB via The Oxford University Clinical Research Unit (OUCRU) in Vietnam. OUCRU is a large-scale clinical and public health research unit with campuses in Ho Chi Minh City and Hanoi. OUCRU is hosted by the Hospital of Tropical Diseases (HTD) in Ho Chi Minh City, and the National Hospital for Tropical Diseases (NHTD) in Hanoi and is a Wellcome Africa and Asia Programme. OUCRU‘s ten-year vision is to have local, regional and global impact on health by leading a locally driven research programme on infectious diseases in Southeast Asia. -
Forschungszentrum Borstel, Leibniz Lungenzentrum
(Germany) is a publicly funded foundation for pulmonary diseases research and clinical care. In UNITE4TB, the Forschungszentrum Borstel will participate in the coordination of clinical trials and will perform biomarker and pathogenomic research.
-
Lygature
(The Netherlands), a not-for-profit foundation, acts as the independent mediator of the consortium, providing governance in terms of progress, finance and collaboration. Since 2006, Lygature has supported close to 100 public-private partnerships in the field of life sciences & health, including poverty-related diseases. -
Lancaster University
(United Kingdom) is a research-intensive university ranked in the UK’s top ten. Around 16,000 students from more than 100 countries choose to study at Lancaster because of our excellent reputation for research, teaching and student satisfaction. Lancaster is a truly global community with international collaborations all over the world and teaching partnerships in China, Malaysia, Ghana and Germany. In UNITE4TB, the Lancaster University team co-leads the work on designing new clinical trials, creating computer simulations to evaluate these designs. -
University College London
(United Kingdom), founded in 1826, is London's leading multidisciplinary university, with more than 13,000 staff and 42,000 students from 150 different countries. Within UCL, UCL-TB is a broad and cross-disciplinary Tuberculosis research network that includes our partners from across the world. Central to UCL-TB are the MRC CTU at UCL and the Centre for Clinical Microbiology (CCM) which work together to provide statistical and microbiological expertise for global TB clinical trials and research. In UNITE4TB, UCL provides this same expertise in the delivery of TB clinical trials. -
TASK
(South Africa) is a clinical research enterprise in healthcare innovation. In UNITE4TB, TASK leads the phase 2A clinical trials for new TB compounds, using novel designs and dosing strategies to achieve quality results faster while maximizing scientific output. TASKS's data will inform the selection of dosages and drug combinations for larger trials.
-
Vita-Salute San Raffaele University (UniSR)
(Italy), internationally recognized among the most prestigious universities, acts as the academic coordinator of the microbiology Work Package within UNITE4TB. UniSR liaises with the other academic and industry partners involved in this task to provide guidance and technical support in all the microbiological aspects. -
Helmholtz Zentrum München
(Germany) is a research center with the mission to discover personalized medical solutions for the prevention and therapy of environmentally-induced diseases and promote a healthier society in a rapidly changing world. It investigates major diseases which develop from the interaction of lifestyle, environmental factors and personal genetic background, focusing particularly on diabetes mellitus, allergies and chronic lung diseases. -
KNCV Tuberculosis Foundation (KNCV)
(The Netherlands) has been fighting TB since its establishment in 1903. Over years, the organization has acquired indispensable knowledge and experience in the field of effective TB prevention and care, resulting in significant contributions to global evidence generation, policy development and TB program implementation worldwide. KNCV supports the implementation of innovative patient support technologies such as digital adherence technologies throughout the project. -
Critical Path Institute, Limited
(Ireland) is a wholly-owned subsidiary of Critical Path Institute, an independent, non-profit established as a public-private partnership. C-Path, Ltd. will lead the data sharing workgroup for UNITE4TB and will assist with machine learning and artificial intelligence efforts. C-Path’s mission is to catalyze the development of new approaches that advance medical innovation and regulatory science, accelerating the path to a healthier world. C-Path, Ltd. EU is in Dublin, Ireland, and C-Path U.S. is in Tucson, Arizona.
-
European Lung Foundation
(United Kingdom) is a patient-led organisation that works internationally to bring patients and the public together with healthcare professionals to improve lung health and advance diagnosis, treatment, and care. ELF works with people from all over the world, including our volunteer patient network of more than 350 people and our patient organisation network with more than 200 respiratory organisations in Europe; working together with people living with more than 40 different lung conditions. -
Instituto de Saude Publica da Universidade do Porto (ISPUP)
(Portugal), a private non-profit association, will lead the establishment of the new UNITE4TB consortium in the existing TB-ecosystem, with focus on the development of health care education and implement online methods of engagement with key stakeholder groups. Since 2015, ISPUP’s has a research group with the focus on Infectious Diseases Epidemiology, which studies diseases such as Mycobacterium tuberculosis, Human Immunodeficiency Virus, Hepatitis B and C. -
University of Liverpool
(United Kingdom) is a UK Russell Group University, active in anti-infective pharmacology, antimicrobial Resistance and Global Health research, which has led or participated in numerous related consortia, including PreDiCT-TB and PanACEA2. -
Institut de Recherche Pour le Developpement
(France), known in English as the French National Research Institute for Sustainable Development (IRD), is a French public research organisation working in partnership with low and middle-resource countries. IRD sets its priorities in line with the Sustainable Development Goals to steer global development and address the environmental, economic, social, and health challenges that affect the planet.
-
University of Hamburg
(Germany) is the largest research and educational institution in Northern Germany and was awarded the status of a ‘University of Excellence’ in 2019. The Department of Clinical Pharmacy at the Institute of Pharmacy is devoted to optimization of anti-infective therapies. -
University of California San Francisco (UCSF)
(USA) was established in 1864 and its School of Medicine is the oldest continuously operating medical school in the western US, is ranked number one in National Institutes of Health funding and is consistently ranked as one of the top five medical schools in the USA. UCSF received $647.8 million in NIH funding in 2018. UCSF’s mission is to advance health worldwide and has the collective faculty and staff to provide leadership, experience and expertise to implement the proposed project. -
TB Alliance
(USA) is a not-for-profit product development partnership dedicated to the discovery, development and delivery of better, faster-acting and affordable tuberculosis drugs that are available to those who need them. Since 2000, TB Alliance has assembled the single largest pipeline of TB drug candidates and is driving equitable access to new treatment regimens. -
FIND
(Switzerland), the global alliance for diagnostics, seeks to ensure equitable access to reliable diagnoses around the world. We connect countries and communities, funders, decision-makers, healthcare providers and developers to spur diagnostic innovation and make testing an integral part of sustainable, resilient health systems. We are working to save 1 million lives through accessible, quality diagnosis, and save US$1 billion in healthcare costs to patients and health systems. We are co-convener of the Access to COVID-19 Tools (ACT) Accelerator diagnostics pillar, and a WHO Collaborating Centre for Laboratory Strengthening and Diagnostic Technology Evaluation.
-
University of Milano (UMIL)
(Italy) is a research university devoted to education and research and is member of the League of European Research Universities (LERU) and founding member of the European Global Health Research Institutes Network (EGHRIN). At UMIL, the Centre for Multidisciplinary Research in Health Science participates in several projects on infectious diseases, including TB, like EU-PEARL. -
University St Andrews
(United Kingdom), founded in the 15th century, is Scotland’s first university and the third oldest in the English-speaking world. It is one of Europe’s most research-intensive seats of learning and one of the top-rated universities in Europe for research, teaching quality, and student satisfaction. In UNITE4TB, St Andrews will contribute to the improvements in speed and quality of tuberculosis clinical trials by researching new methods to monitor response to treatment. -
Uppsala University
(Sweden), the country's only Faculty of Pharmacy, has the scientific breadth required to develop a drug from laboratory to treatment. We perform a significant share of our work in interdisciplinary collaboration, holding key assignments in numerous international consortia. In UNITE4TB, Uppsala University provides expertise in pharmacometric modelling, AI and machine learning to understand the relationships between drug exposure, efficacy and safety. -
European Respiratory Society (ERS)
(Switzerland) is one of the leading medical organisations in the respiratory field, with a growing membership spanning over 160 countries. ERS prioritises science, education and advocacy in order to promote lung health, alleviate suffering from disease and drive standards for respiratory medicine globally.
-
GlaxoSmithKline Investigación y Desarrollo S L (GSK)
(Spain) will bring its expertise in Global Health and tuberculosis research to UNITE4TB as the consortium’s industry lead, mirroring its lead role with ERA4TB, which is investigating earlier stage assets as part of the IMI AMR Accelerator. GSK is a science-led global healthcare company with a special purpose: to help people do more, feel better, live longer. -
Janssen Pharmaceutical NV
(Belgium) The Pharmaceutical Companies of Johnson & Johnson, applies its expertise in the consortium to progress promising anti-TB compounds with the ambition of identifying a universal drug regimen, active against both drug susceptible and resistant TB. For over two decades, Janssen has been a committed partner in the global fight against TB including its development of bedaquiline. -
Otsuka Novel Products GmbH
(Germany) is dedicated to finding innovative solutions to fight the global pandemic of tuberculosis (TB). As the European marketing authorization holder for Deltyba®, Otsuka Novel Products GmbH works in collaboration with the Otsuka group of companies, partners, non-governmental organisations and other stakeholders, to expand global access to Deltyba® and fight multidrug-resistant TB. ONPG is a part of Otsuka Pharmaceutical Company, Ltd., a subsidiary of Otsuka Holdings Co., Ltd. headquartered in Tokyo, Japan. -
Deutsches Zentrum für Infektionsforschung (DZIF)
(Germany), known in English as the German Center for Infection Research, has over 500 researchers from 35 institutions throughout Germany jointly developing new approaches for the prevention, diagnosis and treatment of infectious diseases. The aim is to translate research results into clinical practice quickly and effectively. With this, the DZIF paves the way for developing new vaccines, diagnostic agents and drugs to treat infections.